BranchLab announced a $26 million Series A financing round led by McKesson Ventures, with participation from FCA Venture Partners, Sanofi Ventures, and AIX Ventures. The financing brings the company’s total funding to $35 million.
The company said its platform is designed to modernize pharmaceutical commercialization workflows, including patient identification, audience segmentation, activation, and real-world performance measurement. According to BranchLab, pharmaceutical commercialization has historically depended on fragmented vendors, delayed analytics, and manual operational processes that limit how quickly teams can adapt campaigns and improve outcomes.
BranchLab has developed a unified AI platform that allows pharmaceutical companies and agencies to identify, activate, and optimize high-intent patient and healthcare professional audiences in near real time. The company said the platform has already been adopted by leading pharmaceutical companies and has generated an average increase of nearly 70% in marketing efficacy across multiple therapeutic areas.
The company said its underlying technology uses a transformer-based architecture that trains models within customer-controlled healthcare environments while deploying only non-sensitive demographic and media-side signals. According to BranchLab, the approach enables privacy-first commercialization workflows that compress processes previously taking months into workflows completed within minutes.
The new capital will support expansion of enterprise deployments, deeper integrations across healthcare and media ecosystems, and continued development of the company’s AI commercialization infrastructure platform.
BranchLab said its platform is designed for the evolving privacy landscape and aims to improve commercialization performance without relying on individual-level health information.
KEY QUOTES:
“Pharma has long had access to rich data, but using it quickly—and responsibly—has been the challenge. BranchLab solves this by turning privacy-safe, aggregated data into real-time insights that connect directly to activation. Teams can move faster, reach the right audiences more effectively, and drive better outcomes without relying on sensitive or individual-level information.”
Josh Walsh, CEO, BranchLab
“The more we learned about BranchLab, the more we saw the possibility to transform the way patients learn about and get started on the right therapies. Combining a deep understanding of the patient journey with a future-proofed approach to patient activation could enable an evolved patient therapy experience, one that seamlessly bridges privacy-first audience targeting with patient access, affordability and preference.”
Carrie Williams, Partner, McKesson Ventures
“Pharma has spent years investing in data and analytics, but much of it still lives outside of production systems. BranchLab’s approach to running models within regulated environments and connecting them directly to execution is a fundamental shift in how commercialization can work. We see this as a meaningful step toward making pharma’s data, and activation systems work together in real time.”
Andrew Bouldin, Managing Partner, FCA Venture Partners
“Healthcare is entering a new era of responsible AI within regulated environments. BranchLab has the potential to become a core commercial intelligence layer, putting this capability directly in the hands of pharma teams to connect therapies with patients across next-generation digital environments.”
Cris De Luca, Sanofi Ventures
